const items = { "cd19" : `
  <h1 class="subtitle">CD19</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02348216?recrs=abd&type=Intr&lead=Kite&fund=2&rank=9">KTE-C19_Kite_Hema_1/2_US/Canada/Germany/Israel/Netherlands_200_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/study/NCT02601313?recrs=abd&type=Intr&lead=Kite&fund=2&rank=8&show_locs=Y#locn">KTE-C19_Kite_RR-MCL_2_US/France_80_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02614066?recrs=abd&type=Intr&lead=Kite&fund=2&rank=7">KTE-C19_Kite_ALL_1/2_US/Canada_75_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02625480?recrs=abd&type=Intr&lead=Kite&fund=2&rank=6">KTE-C19_Kite_ALL_1/2_US/Canada_75_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03105336?recrs=abd&type=Intr&lead=Kite&fund=2&rank=5">KTE-C19_Kite_FL/NHL_2_US_50_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02926833?recrs=abd&type=Intr&lead=Kite&fund=2&rank=1">KTE-C19+atezolizumab(anti-PD-L1)_Kite_R-DLBCL_1/2_US_31_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03391466?recrs=abd&type=Intr&lead=Kite&fund=2&rank=2">KTE-C19_Kite_RR-DLBCL_3_US_350_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02631044?type=Intr&lead=Juno&fund=2&rank=2">JCAR017_Juno_Hema_1_US_274_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03483103?type=Intr&lead=Juno&fund=2&rank=1">JCAR017_Juno_Hema_2_US_56_Adult/Senior</a></li>    
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03331198?type=Intr&lead=Juno&fund=2&rank=4">JCAR017_Juno_Hema_1/2_US_205_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02706405">JCAR014_FHCRC_Hema_1_US_42_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03166878?term=UCAR&rank=2">UCART019_China-PLA_B-Cell-Malignancy_1/2_China_80_Child/Adult/Senior</a></li>
  </ul>
`, "bcma": `
  <h1 class="subtitle">BCMA</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03318861?recrs=abd&type=Intr&lead=Kite&fund=2&rank=3">KITE-585_Kite_MM_1_US_64_Adult/Senior</a></li> 
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03430011?type=Intr&lead=Juno&fund=2&rank=3">JCARH125_Juno_MM_1/2_US_118_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03070327">EGFRt/BCMA-41BBz-CAR-T-Cell_Memorial-Sloan-Kettering-Cancer-Center_MM_1_US_36_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03274219?type=Intr&lead=Bluebird+Bio&fund=2&rank=1">bb21217_Bluebird_MM_1_US_50_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02658929?term=bb2121&rank=2">bb2121_Celgene_MM_1_US_46_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03361748?term=bb2121&rank=1">bb2121_Celgene_MM_2_US/Spain_94_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03288493?lead=Poseida&rank=1">P-BCMA-101-Car-T-Cells_Poseida_MM_1_US_40_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03090659?lead=Legend&rank=1">LCAR-B38M-CAR-T-Cell_Nanjing-Legend-Biotech_MM_1/2_China_100_Adult/Senior</a></li>
  </ul>
`, "cd20": `
  <h1 class="subtitle">CD19/CD20</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03019055?term=CD19%2FCD20&rank=11">CAR-20/19-T_MCW_ALL_1_US_24_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03097770?term=CD19%2FCD20&rank=3">Tandem-anti-CD19/20-CAR-T_China-PLA_B-cell-Malignancy_1/2_China_20_Child/Adult/Senior</a></li>
  </ul>
`, "cd22": `
  <h1 class="subtitle">CD19/CD22</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03289455?lead=Autolus&rank=1">AUTO3_Autolus_ALL_1_UK_50_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03287817?lead=Autolus&rank=2">AUTO3_Autolus_DLBCL_1/2_UK_120_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03185494?term=CD19%2FCD20&rank=4">Tandem-anti-CD19/22-CAR-T_China-PLA_B-Cell-Malignancy_1/2_China_30_Child/Adult/Senior</a></li>
  </ul>
`, "hbb": `
  <h1 class="subtitle">HBB</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02906202?type=Intr&lead=Bluebird+Bio&fund=2&rank=3">LentiGlobin®-BB305_Bluebird_β-Thalassemia_3_US/France/Germany/Greece/Italy/Thailand/UK_23_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03207009?type=Intr&lead=Bluebird+Bio&fund=2&rank=2">LentiGlobin®-BB305_Bluebird_β-Thalassemia_3_US/France/Germany/Greece/Italy/UK_15_Child/Adult</a></li>
  </ul>
`, "ny": `
  <h1 class="subtitle">NY</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01892293">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Sarcoma_1/2_US/Canada/France/UK_65_Child/Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01350401?type=Intr&lead=adaptimmune&fund=2&rank=11">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_mMelanoma_1/2_US_4_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01352286?lead=Adaptimmune&draw=2&rank=13">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1/2_US_26_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01567891?lead=Adaptimmune&rank=12">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Ovarian-Cancer_1/2_US_10_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01892293?lead=Adaptimmune&rank=11">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1/2_US_10_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02588612?lead=Adaptimmune&rank=10">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_NSCLC_1/2_US_10_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02992743?lead=Adaptimmune&rank=6">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Liposarcoma_1/2_US_15_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03168438?lead=Adaptimmune&rank=3">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1_US_20_Adult/Senior</a></li>
  </ul>
`, "ebv": `
  <h1 class="subtitle">EBV</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02578641?recrs=ad&lead=Tessa&fund=2&rank=1">autologous-EBV-specific-Cytotoxic-T-Lymphocytes_Tessa_Advanced-Nasopharyngeal-Carcinoma_3_US/Malaysia/Singapore/Taiwan/Thailand_330_Adult/Senior</a></li>
  </ul>
`, "hbv": `
  <h1 class="subtitle">HBV</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02686372?lead=TCR&rank=2">HBV/TCR-T-Cell_Lion-TCR-Pte_HCC_1_China_10_Adult</a></li>
  </ul>
`, "other": `
  <h1 class="subtitle">Other</h1>
  <hr />
  <ul>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03139370?recrs=abd&type=Intr&lead=Kite&fund=2&rank=4">MAGE-A3/A6_KITE-718_Kite_HLA-DPB1+_1_US_50_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02315612">CD22_JCAR018_NCI/Juno_Hema_1_US_115_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02408016">WT1_Autologous-WT1-JCTAR016_FHCRC_NSCLC_1/2_US_20_Adult_Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02311621">CD171/L1CAM_JCAR023_Seattle-Children's-Hospital/Juno_GBM_1_US_40_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02498912">MUC16_JCAR020_Memorial-Sloan-Kettering-Cancer-Center_Solid-Tumors_1_US_30_Adult/Senior </a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02706392">ROR1_JCAR024_FHCRC_Hema_1_US_60_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01745120?type=Intr&lead=Bluebird+Bio&fund=2&rank=7">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_β-Thalassemia_1/2_US/Australia/Thailand_18_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02151526?type=Intr&lead=Bluebird+Bio&fund=2&rank=4">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_β-Thalassemia_1/2_France_7_Child/Adult</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02140554?type=Intr&lead=Bluebird+Bio&fund=2&rank=5">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_Sickle-Cell-Disease_1_US_29_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03190278?type=Intr&lead=Cellectis+S.A.&fund=2&rank=2">CD123_UCART123_Cellectis-S.A._AML_1_US_156_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03203369?type=Intr&lead=Cellectis+S.A.&fund=2&rank=1">CD123_UCART123_Cellectis-S.A._BPDCN_1_US_72_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03287804?lead=Autolus&rank=3">BCMA+TACI_AUTO2_Autolus_MM_1/2_UK_80_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02592577?lead=Adaptimmune&rank=9">MAGE-A10_MAGEA10ᶜ⁷⁹⁶T_Adaptimmune_NSCLC_1_US/Canada/Spain/UK_28_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02989064?lead=Adaptimmune&rank=7">MAGE-A10_MAGEA10ᶜ⁷⁹⁶T_Adaptimmune_MAGE-A10_1_US/Canada_22_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03132792?lead=Adaptimmune&rank=5">AFP_AFPᶜ³³²T_Adaptimmune_HCC_1_US/Spain/UK_30_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03132922?lead=Adaptimmune&rank=4">MAGE_A4_MAGE-A4ᶜ¹º³²T_Adaptimmune_Solid-Tumors_1_US/Canada_32_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03319459?lead=Fate&rank=1">FATE-NK100_Fate_Solid-Tumors_1_US_100_Adult/Senior</a></li>
    <li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02743351?lead=Fate&rank=2">Hematopoietic-Cell-Transplantation_ProTmune_Fate_Hema_1/2_US_70_Adult/Senior</a></li>
  </ul>
`};

const itemList = [
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02348216?recrs=abd&type=Intr&lead=Kite&fund=2&rank=9">KTE-C19_Kite_Hema_1/2_US/Canada/Germany/Israel/Netherlands_200_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/study/NCT02601313?recrs=abd&type=Intr&lead=Kite&fund=2&rank=8&show_locs=Y#locn">KTE-C19_Kite_RR-MCL_2_US/France_80_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02614066?recrs=abd&type=Intr&lead=Kite&fund=2&rank=7">KTE-C19_Kite_ALL_1/2_US/Canada_75_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02625480?recrs=abd&type=Intr&lead=Kite&fund=2&rank=6">KTE-C19_Kite_ALL_1/2_US/Canada_75_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03105336?recrs=abd&type=Intr&lead=Kite&fund=2&rank=5">KTE-C19_Kite_FL/NHL_2_US_50_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02926833?recrs=abd&type=Intr&lead=Kite&fund=2&rank=1">KTE-C19+atezolizumab(anti-PD-L1)_Kite_R-DLBCL_1/2_US_31_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03391466?recrs=abd&type=Intr&lead=Kite&fund=2&rank=2">KTE-C19_Kite_RR-DLBCL_3_US_350_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02631044?type=Intr&lead=Juno&fund=2&rank=2">JCAR017_Juno_Hema_1_US_274_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03483103?type=Intr&lead=Juno&fund=2&rank=1">JCAR017_Juno_Hema_2_US_56_Adult/Senior</a></li>    `,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03331198?type=Intr&lead=Juno&fund=2&rank=4">JCAR017_Juno_Hema_1/2_US_205_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02706405">JCAR014_FHCRC_Hema_1_US_42_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03166878?term=UCAR&rank=2">UCART019_China-PLA_B-Cell-Malignancy_1/2_China_80_Child/Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03318861?recrs=abd&type=Intr&lead=Kite&fund=2&rank=3">KITE-585_Kite_MM_1_US_64_Adult/Senior</a></li> `,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03430011?type=Intr&lead=Juno&fund=2&rank=3">JCARH125_Juno_MM_1/2_US_118_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03070327">EGFRt/BCMA-41BBz-CAR-T-Cell_Memorial-Sloan-Kettering-Cancer-Center_MM_1_US_36_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03274219?type=Intr&lead=Bluebird+Bio&fund=2&rank=1">bb21217_Bluebird_MM_1_US_50_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02658929?term=bb2121&rank=2">bb2121_Celgene_MM_1_US_46_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03361748?term=bb2121&rank=1">bb2121_Celgene_MM_2_US/Spain_94_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03288493?lead=Poseida&rank=1">P-BCMA-101-Car-T-Cells_Poseida_MM_1_US_40_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03090659?lead=Legend&rank=1">LCAR-B38M-CAR-T-Cell_Nanjing-Legend-Biotech_MM_1/2_China_100_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03019055?term=CD19%2FCD20&rank=11">CAR-20/19-T_MCW_ALL_1_US_24_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03097770?term=CD19%2FCD20&rank=3">Tandem-anti-CD19/20-CAR-T_China-PLA_B-cell-Malignancy_1/2_China_20_Child/Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03289455?lead=Autolus&rank=1">AUTO3_Autolus_ALL_1_UK_50_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03287817?lead=Autolus&rank=2">AUTO3_Autolus_DLBCL_1/2_UK_120_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03185494?term=CD19%2FCD20&rank=4">Tandem-anti-CD19/22-CAR-T_China-PLA_B-Cell-Malignancy_1/2_China_30_Child/Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02906202?type=Intr&lead=Bluebird+Bio&fund=2&rank=3">LentiGlobin®-BB305_Bluebird_β-Thalassemia_3_US/France/Germany/Greece/Italy/Thailand/UK_23_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03207009?type=Intr&lead=Bluebird+Bio&fund=2&rank=2">LentiGlobin®-BB305_Bluebird_β-Thalassemia_3_US/France/Germany/Greece/Italy/UK_15_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01892293">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Sarcoma_1/2_US/Canada/France/UK_65_Child/Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01350401?type=Intr&lead=adaptimmune&fund=2&rank=11">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_mMelanoma_1/2_US_4_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01352286?lead=Adaptimmune&draw=2&rank=13">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1/2_US_26_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01567891?lead=Adaptimmune&rank=12">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Ovarian-Cancer_1/2_US_10_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01892293?lead=Adaptimmune&rank=11">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1/2_US_10_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02588612?lead=Adaptimmune&rank=10">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_NSCLC_1/2_US_10_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02992743?lead=Adaptimmune&rank=6">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_Liposarcoma_1/2_US_15_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03168438?lead=Adaptimmune&rank=3">NY-ESO-1ᶜ²⁵⁹T_Adaptimmune_MM_1_US_20_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02578641?recrs=ad&lead=Tessa&fund=2&rank=1">autologous-EBV-specific-Cytotoxic-T-Lymphocytes_Tessa_Advanced-Nasopharyngeal-Carcinoma_3_US/Malaysia/Singapore/Taiwan/Thailand_330_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02686372?lead=TCR&rank=2">HBV/TCR-T-Cell_Lion-TCR-Pte_HCC_1_China_10_Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03139370?recrs=abd&type=Intr&lead=Kite&fund=2&rank=4">MAGE-A3/A6_KITE-718_Kite_HLA-DPB1+_1_US_50_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02315612">CD22_JCAR018_NCI/Juno_Hema_1_US_115_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02408016">WT1_Autologous-WT1-JCTAR016_FHCRC_NSCLC_1/2_US_20_Adult_Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02311621">CD171/L1CAM_JCAR023_Seattle-Children's-Hospital/Juno_GBM_1_US_40_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02498912">MUC16_JCAR020_Memorial-Sloan-Kettering-Cancer-Center_Solid-Tumors_1_US_30_Adult/Senior </a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02706392">ROR1_JCAR024_FHCRC_Hema_1_US_60_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT01745120?type=Intr&lead=Bluebird+Bio&fund=2&rank=7">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_β-Thalassemia_1/2_US/Australia/Thailand_18_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02151526?type=Intr&lead=Bluebird+Bio&fund=2&rank=4">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_β-Thalassemia_1/2_France_7_Child/Adult</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02140554?type=Intr&lead=Bluebird+Bio&fund=2&rank=5">Beta-Hemoglobinopathies_LentiGlobin®-BB305_Bluebird_Sickle-Cell-Disease_1_US_29_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03190278?type=Intr&lead=Cellectis+S.A.&fund=2&rank=2">CD123_UCART123_Cellectis-S.A._AML_1_US_156_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03203369?type=Intr&lead=Cellectis+S.A.&fund=2&rank=1">CD123_UCART123_Cellectis-S.A._BPDCN_1_US_72_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03287804?lead=Autolus&rank=3">BCMA+TACI_AUTO2_Autolus_MM_1/2_UK_80_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02592577?lead=Adaptimmune&rank=9">MAGE-A10_MAGEA10ᶜ⁷⁹⁶T_Adaptimmune_NSCLC_1_US/Canada/Spain/UK_28_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02989064?lead=Adaptimmune&rank=7">MAGE-A10_MAGEA10ᶜ⁷⁹⁶T_Adaptimmune_MAGE-A10_1_US/Canada_22_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03132792?lead=Adaptimmune&rank=5">AFP_AFPᶜ³³²T_Adaptimmune_HCC_1_US/Spain/UK_30_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03132922?lead=Adaptimmune&rank=4">MAGE_A4_MAGE-A4ᶜ¹º³²T_Adaptimmune_Solid-Tumors_1_US/Canada_32_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03319459?lead=Fate&rank=1">FATE-NK100_Fate_Solid-Tumors_1_US_100_Adult/Senior</a></li>`,
  `<li><a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT02743351?lead=Fate&rank=2">Hematopoietic-Cell-Transplantation_ProTmune_Fate_Hema_1/2_US_70_Adult/Senior</a></li>`
];

const contentList = [`
  <tr>
    <td>KTE-C19
    Biological: axicabtagene ciloleucel
    (Autologous genetically modified anti-CD19 CAR transduced T cells)</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Refractory Diffuse Large B Cell Lymphoma
    Refractory Primary Mediastinal B Cell Lymphoma
    Refractory Transformed Follicular Lymphoma
    Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma
    Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma
    Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
    Relapsed/Refractory Large B Cell Lymphoma Including DLBCL, PMBCL, TFL and HGBCL After Two Systemic Lines of Therapy" in Phase 2 Expanded Cohorts</td>
    <td>Hema</td>
    <td>US, Canada, Germany, Israel, Netherlands</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Relapsed/Refractory Mantle Cell Lymphoma</td>
    <td>RR MCL</td>
    <td>US, France</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Acute Lymphoblastic Leukemia</td>
    <td>ALL</td>
    <td>US, Canada</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Acute Lymphoblastic Leukemia</td>
    <td>ALL</td>
    <td>US, Canada</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Follicular Lymphoma
    Marginal Zone Lymphoma
    Indolent Non-Hodgkin Lymphoma</td>
    <td>FL/NHL</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19+atezolizumab (anti-PD-L1)</td>
    <td>Kite, A Gilead Company </td>
    <td>CD19</td>
    <td>Refractory Diffuse Large B Cell Lymphoma</td>
    <td>R DLBCL</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>KTE-C19 Biological: axicabtagene ciloleucel</td>
    <td>Kite, A Gilead Company</td>
    <td>CD19</td>
    <td>Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</td>
    <td>RR DLBCL</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR017 Biological: lisocabtagene maraleucel</td>
    <td>Juno Therapeutics, Inc. </td>
    <td>CD19</td>
    <td>Lymphoma, Non-Hodgkin
    Lymphoma, Nonhodgkin
    Lymphoma, B-Cell
    Lymphoma, Large B-Cell, Diffuse</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR017</td>
    <td>Juno Therapeutics, Inc.</td>
    <td>CD19</td>
    <td>Non-Hodgkin Lymphoma
    Diffuse Large B Cell Lymphoma
    Follicular Lymphoma
    Mantle-cell Lymphoma
    Primary Mediastinal B-cell Lymphoma</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR017</td>
    <td>Juno Therapeutics, Inc.</td>
    <td>CD19</td>
    <td>Leukemia, Lymphocytic, Chronic, B-Cell
    Lymphoma, Small Lymphocytic</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes) + durvalumab</td>
    <td>Fred Hutchinson Cancer Research Center 
    Collaborators:
    AstraZeneca
    Juno Therapeutics, Inc.
    MedImmune LLC
    National Cancer Institute (NCI)</td>
    <td>CD19</td>
    <td>BCL2 Gene Rearrangement
    BCL6 Gene Rearrangement
    CD19 Positive
    Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
    MYC Gene Rearrangement
    Recurrent Diffuse Large B-Cell Lymphoma
    Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Refractory Diffuse Large B-Cell Lymphoma
    Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>UCART019</td>
    <td>Chinese PLA General Hospital </td>
    <td>CD19</td>
    <td>B Cell Leukemia B Cell Lymphoma</td>
    <td>B-cell Malignancy</td>
    <td>China</td>
  </tr>
`, `
  <tr>
    <td>KITE-585(Autologous genetically modified anti-BCMA CAR transduced T cells)</td>
    <td>Kite, A Gilead Company</td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCARH125</td>
    <td>Juno Therapeutics, Inc.</td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>EGFRt/BCMA-41BBz CAR T cell </td>
    <td>Memorial Sloan Kettering Cancer Center Collaborator: Juno Therapeutics, Inc.</td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>bb21217 (autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution)</td>
    <td>Bluebird bio </td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>bb2121 (autologous T cells transduced ex-vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution)</td>
    <td>Celgene Collaborator: Bluebird bio</td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>bb2121</td>
    <td>Celgene</td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US, Spain</td>
  </tr>
`, `
  <tr>
    <td> P-BCMA-101 CAR-T cells (P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired.)</td>
    <td>Poseida Therapeutics, </td>
    <td>BCMA</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>LCAR-B38M CAR-T cell </td>
    <td>Nanjing Legend Biotech Co.</td>
    <td>BCMA</td>
    <td>Refractory or Relapsed Multiple Myeloma</td>
    <td>MM</td>
    <td>China</td>
  </tr>
`, `
  <tr>
    <td>CAR-20/19-T 
    (CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains)</td>
    <td>Medical College of Wisconsin</td>
    <td>CD19 + CD20 </td>
    <td>CLL/SLL
    Lymphomas Non-Hodgkin's B-Cell</td>
    <td>ALL</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>Tandem anti-CD19/20 CAR T </td>
    <td>Chinese PLA General Hospital </td>
    <td>CD19 + CD20 </td>
    <td>Relapsed and/or Chemotherapy Refractory B-cell Malignancy</td>
    <td>B-cell Malignancy</td>
    <td>China</td>
  </tr>
`, `
  <tr>
    <td>AUTO3 
    (CD19/CD22 Autologous CAR-T Therapy)</td>
    <td>Autolus</td>
    <td>CD19/CD22</td>
    <td>B Acute Lymphoblastic Leukemia
    Recurrent Childhood Acute Lymphoblastic Leukemia
    Refractory Childhood Acute Lymphoblastic Leukemia
    B-cell Acute Lymphoblastic Leukemia</td>
    <td>ALL</td>
    <td>UK</td>
  </tr>
`, `
  <tr>
    <td>AUTO3 
  (CD19/CD22 Autologous CAR-T Therapy)</td>
    <td>Autolus</td>
    <td>CD19/CD22</td>
    <td>Diffuse Large B Cell Lymphoma
    Relapsed Diffuse Large B-Cell Lymphoma
    Refractory Diffuse Large B-Cell Lymphoma
    DLBCL</td>
    <td>DLBCL
    <td>UK</td>
  </tr>
`, `
  <tr>
    <td>Tandem anti-CD19/22 CAR T </td>
    <td>Chinese PLA General Hospital </td>
    <td>CD19 + CD22 </td>
    <td>Relapsed and/or Chemotherapy Refractory B-cell Malignancy</td>
    <td>B-cell Malignancy</td>
    <td>China</td>
  </tr>
`, `
  <tr>
    <td>LentiGlobin® BB305</td>
    <td>Bluebird bio </td>
    <td>β0 mutation at either alleles of the β-globin (HBB) gene</td>
    <td>Transfusion-dependent β-Thalassemia without β0/β0 Genotype</td>
    <td>β-Thalassemia</td>
    <td>US, France, Germany, Greece, Italy, Thailand, UK</td>
  </tr>
`, `
  <tr>
    <td>LentiGlobin® BB305</td>
    <td>Bluebird bio </td>
    <td>β0 mutation at both alleles of the β-globin (HBB) gene</td>
    <td>Transfusion-dependent β-Thalassemia with β0/β0 Genotype</td>
    <td>β-Thalassemia</td>
    <td>US, France, Germany, Greece, Italy, UK</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T cells (autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR)</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>HLA-A2+ Patients With Synovial Sarcoma</td>
    <td>Sarcoma</td>
    <td>US, Canada, France, UK</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T cells</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>Metastatic Melanoma that expresses cancer testis antigen NYESO-1 and be HLA-A*02 positive</td>
    <td>Metastatic Melanoma</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>HLA-A2+ Patients With Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>Ovarian Cancer</td>
    <td>Ovarian Cancer</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>HLA-A201 positive and test positive for expression of NY-ESO-1 and/or LAGE-1 Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>HLA-A*0201, HLA-A*0205 and/or HLA-A*0206 positive subjects with advanced (Stage IIIb or IV) NSCLC</td>
    <td>NSCLC</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>Myxoid Round Cell Liposarcoma
    High Grade Myxoid Liposarcoma</td>
    <td>Liposarcoma</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>NY-ESO-1ᶜ²⁵⁹T alone or in combination with pembrolizumab</td>
    <td>Adaptimmune</td>
    <td>NY-ESO-1 </td>
    <td>Multiple Myeloma
    Refractory Multiple Myeloma</td>
    <td>MM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>autologous EBV specific Cytotoxic T Lymphocytes</td>
    <td>Tessa Therapeutics</td>
    <td>EBV</td>
    <td>Advanced Nasopharyngeal Carcinoma</td>
    <td>Advanced Nasopharyngeal Carcinoma</td>
    <td>US, Malaysia, Singapore, Taiwan, Thailand</td>
  </tr>
`, `
  <tr>
    <td>HBV/TCR-T cell 
    (HBV antigen specific TCR redirected T cell)</td>
    <td>Lion TCR Pte. Ltd. </td>
    <td>HBV</td>
    <td>Hepatitis B virus (HBV) related HCC after liver transplantation</td>
    <td>HCC</td>
    <td>China</td>
  </tr>
`, `
  <tr>
    <td>KITE-718 (Autologous genetically modified MAGE-A3/A6 TCR transduced T cells)</td>
    <td>Kite, A Gilead Company</td>
    <td> MAGE-A3/A6 (Diagnostic Test)</td>
    <td>HLA-DPB1*04:01 Positive Subjects With Advanced Cancers</td>
    <td>HLA-DPB1+</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR018</td>
    <td>National Cancer Institute (NCI) Also posted on company website of Juno Therapeutics, Inc.</td>
    <td>CD22</td>
    <td>Follicular Lymphoma ALL NHL Large Cell Lymphoma</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>Autologous WT1-JCTAR016 Biological: Aldesleukin (TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes)</td>
    <td>Fred Hutchinson Cancer Research Center Collaborator:National Cancer Institute (NCI) Also posted on company website of Juno Therapeutics, Inc.</td>
    <td>WT1 (Wilms tumor 1)</td>
    <td>Stage III-IV Non-small Cell Lung Cancer or Mesothelioma</td>
    <td>NSCLC</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR023
    [Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
    Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)]</td>
    <td>Seattle Children's Hospital 
    Also posted on company website of Juno Therapeutics, Inc.</td>
    <td> CD171/L1CAM</td>
    <td>Neuroblastoma
    Ganglioneuroblastoma</td>
    <td>GBM</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR020
    (4H11-28z/fIL-12/EFGRt+ T cells)</td>
    <td>Memorial Sloan Kettering Cancer Center 
    Collaborators:
    Stanford University
    Juno Therapeutics, Inc</td>
    <td>MUC16</td>
    <td>Ovarian Cancer, Solid Tumors</td>
    <td>Solid Tumors</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>JCAR024 </td>
    <td>Fred Hutchinson Cancer Research Center 
    Collaborator:
    National Cancer Institute (NCI)
    Also posted on company website of Juno Therapeutics, Inc.</td>
    <td>ROR1
    (receptor tyrosine kinase-like orphan receptor 1 )</td>
    <td>Recurrent Adult Acute Lymphoblastic Leukemia
    Recurrent Mantle Cell Lymphoma
    Refractory Chronic Lymphocytic Leukemia
    Stage IV Breast Cancer AJCC v6 and v7
    Stage IV Non-Small Cell Lung Cancer AJCC v7
    Triple-Negative Breast Carcinoma</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>LentiGlobin® BB305</td>
    <td>Bluebird bio </td>
    <td>Beta-Hemoglobinopathies</td>
    <td>β-Thalassemia Major</td>
    <td>β-Thalassemia</td>
    <td>US, Australia, Thailand</td>
  </tr>
`, `
  <tr>
    <td>LentiGlobin® BB305</td>
    <td>Bluebird bio </td>
    <td>Beta-Hemoglobinopathies</td>
    <td>Beta-Thalassemia Major
    Sickle Cell Disease</td>
    <td>β-Thalassemia</td>
    <td>France</td>
  </tr>
`, `
  <tr>
    <td>LentiGlobin® BB305
    (Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector)</td>
    <td>Bluebird bio </td>
    <td>Beta-Hemoglobinopathies</td>
    <td>Sickle Cell Disease</td>
    <td>Sickle Cell Disease</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>UCART123
    (Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen)</td>
    <td>Cellectis S.A. </td>
    <td>CD123</td>
    <td>Acute Myeloid Leukemia</td>
    <td>AML</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>UCART123 </td>
    <td>Cellectis S.A. </td>
    <td>CD123</td>
    <td>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</td>
    <td>BPDCN</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>AUTO2 
  [AUTO2 has a dual target BCMA (B cell maturation antigen) and TACI (Transmembrane activator and calcium modulator and cyclophilin ligand interactor)]</td>
    <td>Autolus</td>
    <td>BCMA + TACI</td>
    <td>Multiple Myeloma</td>
    <td>MM</td>
    <td>UK</td>
  </tr>
`, `
  <tr>
    <td> MAGEA10ᶜ⁷⁹⁶T
    (autologous genetically modified T cells transduced to express the high affinity MAGEA10ᶜ⁷⁹⁶ TCR)
  </td>
    <td>Adaptimmune</td>
    <td>MAGE A10 </td>
    <td>a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and a tumor test positive for MAGE A10 protein expression (protein or gene) Advanced NSCLC</td>
    <td>NSCLC</td>
    <td>US, Canada, Spain, UK</td>
  </tr>
`, `
  <tr>
    <td> MAGEA10ᶜ⁷⁹⁶T</td>
    <td>Adaptimmune</td>
    <td>MAGE A10 </td>
    <td>Urinary Bladder Cancer
    Head and Neck Cancer
    Melanoma that has the MAGE-A10 protein expressed</td>
    <td>MAGE-A10</td>
    <td>US, Canada</td>
  </tr>
`, `
  <tr>
    <td>AFPᶜ³³²T</td>
    <td>Adaptimmune</td>
    <td>AFP </td>
    <td>HLA-A *02:01 positive, AFP positive, histologically confirmed measurable  advanced hepatocellular cancer (HCC)</td>
    <td>HCC</td>
    <td>US, Spain, UK</td>
  </tr>
`, `
  <tr>
    <td>MAGE-A4ᶜ¹º³²T </td>
    <td>Adaptimmune</td>
    <td>MAGE A4 </td>
    <td>HLA-A*02 subjects with MAGE-A4 positive locally advanced inoperable or metastatic cancer of the following types: urinary bladder, melanoma, head and neck (squamous cell), ovarian, NSCLC (squamous, adenosquamous or large cell), esophageal (squamous and adenocarcinoma) and gastric.</td>
    <td>Solid Tumors</td>
    <td>US, Canada</td>
  </tr>
`, `
  <tr>
    <td>FATE-NK100
    ( a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity); 
    + Trastuzumab; or
    +Cetuximab
  </td>
    <td>Fate Therapeutics</td>
    <td></td>
    <td>monotherapy: advanced solid tumor malignancies
    +Transtuzumab: human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors.
    +Cetuximab: advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors</td>
    <td>Solid Tumors</td>
    <td>US</td>
  </tr>
`, `
  <tr>
    <td>ProTmune
    (ex vivo programmed mobilized peripheral blood cells for Allogeneic Hematopoietic Cell Transplantation)</td>
    <td>Fate Therapeutics</td>
    <td>Hematopoietic Cell Transplantation</td>
    <td>Hematologic Malignancies
    Acute Myeloid Leukemia
    Acute Lymphoblastic Leukemia
    Myelodysplastic Syndromes
    Chronic Myelogenous Leukemia</td>
    <td>Hema</td>
    <td>US</td>
  </tr>
`];

const notFound = "<p style = 'color : #CB7BCB; font-size: 30px' >No Result</p>";

let activeItemId = "cd19";
let mainContent = $("#main-content");
mainContent.html(items[activeItemId]);

$(".list-group > a").click((e) => {
  let itemId = e.target.id;
  $(document.getElementById(activeItemId)).removeClass("active");
  activeItemId = itemId;
  $(document.getElementById(itemId)).addClass("active");
  mainContent.html(items[itemId]);
});

$(".searchbar button").click((e) => {
  $(document.getElementById(activeItemId)).removeClass("active");
  activeItemId = undefined;
  let keyword = $(".searchbar input").val();
  $(".searchbar input").val("");
  let result = itemList.filter((item, idx) => {
    return contentList[idx].toLowerCase().search(keyword.toLowerCase()) !== -1 || item.toLowerCase().search(keyword.toLowerCase()) !== -1;
  });
  mainContent.html(`  
    <h1 class="subtitle">Search Result</h1>
    <hr />
    <ul>
      ${result.length == 0 ? notFound : result.join("")}
    </ul>
  `);
});